lifestyle.thedishh.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Septerna, Inc.
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
March 1, 2026
Septerna to Present at TD Cowen 46th Annual Health Care Conference
February 24, 2026
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2026
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
February 10, 2026